Postoperative immunohistochemical results revealed that 54 patients were Luminal A breast cancer, 8 patients were Luminal B breast cancer, 17 were HER2+ breast cancer and 25 patients were triple-negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.